文献速递医院感染防控新发突发、热带与寄生虫病真菌感染

CD19 CAR-T治疗后长期生存者持续存在病原体特异性感染风险:澳大利亚多中心队列研究

Persistent and pathogen-specific infection risk during long-term survivorship after CD19 chimeric antigen receptor T-cell therapy: an Australian multicentre cohort study.
PubMed 文献 · Clin Microbiol Infect · 2026-06-24

该澳大利亚五中心回顾性队列纳入2019至2023年接受标准CD19 CAR-T治疗的291例侵袭性淋巴瘤成人患者,随访至2025年3月。49.5%发生至少一次感染,5%发生致命感染;可评估的146例中40%在1年后发生迟发感染,呼吸道病毒感染最常见且重度比例未随时间下降。真菌感染虽少见,但与大剂量地塞米松暴露及既往细菌感染相关。

要点

  • CD19 CAR-T后近半数患者发生感染,5%为致命性感染。
  • 1年后迟发感染仍常见,呼吸道病毒为主要来源且重度比例不降。
  • 早期感染与31至365天感染风险相关,但1年后感染无明确预测因素。

核心结论

  • CD19 CAR-T治疗后迟发感染常见且具有临床意义,呼吸道病毒是主要致病来源。
  • 真菌感染风险与超过6个月的糖皮质激素暴露相关,支持首年后持续进行感染监测与预防。

研究设计与样本

  • 澳大利亚五中心回顾性队列研究,纳入2019至2023年接受标准CD19 CAR-T的侵袭性淋巴瘤成人患者,随访至2025年3月。
  • 共纳入291例患者,采用共识定义将感染分为微生物学确认或临床定义,并以死亡为竞争风险进行病因特异性Cox回归。

主要发现

  • 291例中49.5%(144/291)发生至少一次感染(共249次事件),36%(106/291)发生CTCAE≥3级重度感染,5%(16/291)发生致命感染。
  • 146例可评估1年后感染的患者(中位随访600天,IQR 420-900)中,40%(57/146)发生迟发感染,18%(27/146)发生重度迟发感染。
  • 迟发感染中呼吸道病毒感染最常见(37/89次事件),且重度呼吸道病毒感染比例未随时间下降。
  • 早期感染与31至365天感染相关(OR 2.96;95%CI 1.32-6.87;p 0.009),但未发现1年后感染的预测因素。
  • 真菌感染占队列6%(17/291),多变量分析显示地塞米松累积暴露和既往细菌感染与侵袭性真菌病相关(p<0.05)。

关键数值与推荐

  • 首发28天内≥56 mg地塞米松等效剂量可预测真菌感染风险(95%CI 1.6-27.1;AUC 0.71;p 0.015)。
  • 感染严重程度按CTCAE分级,≥3级定义为重度感染。

临床怎么用

  • CD19 CAR-T后应持续进行感染监测与预防,尤其关注首年后的迟发感染。
  • 对接受高累积剂量糖皮质激素的患者应警惕真菌感染风险。
  • 呼吸道病毒感染在迟发感染中占比高且重度比例不降,需考虑相应预防策略。

局限性

  • 本研究为回顾性队列研究,可能存在残余混杂。
  • 1年后可评估感染的患者样本量有限(146例),可能影响预测因素识别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Infection remains the leading cause of nonrelapse mortality after CD19 chimeric antigen receptor T-cell (CAR-T) therapy. However, the aetiology and risk of late infections, particularly beyond 1 year after infusion, remain poorly defined. METHODS: This national multicentre retrospective cohort study included adults receiving standard-of-care CD19 CAR-T for aggressive lymphoma across five Australian centres between 2019 and 2023, with follow-up to March 2025. Infections were classified as microbiologically confirmed or clinically defined using consensus definitions. Outcomes included infection incidence, timing, microbiological aetiology, and pathogen-specific risk factors. Cause-specific Cox proportional hazards regression, with death as a competing risk, evaluated risks for microbiologically confirmed infections and early (day 0-30), medium (day 31-365), and late (≥365 days) infection events, with Firth regression used for sensitivity analyses. RESULTS: Among 291 patients, 49.5% (144/291) experienced ≥1 infection (249 events); 36% (106/291) developed a severe infection (grade ≥3 Common Terminology Criteria for Adverse Events [CTCAE] and 5% (16/291) suffered a fatal infection. Of 146 patients evaluable after 1 year (median follow-up, 600 days; interquartile range, 420-900), 40% experienced a late infection (57/146) and 18% (27/146) a severe late infection. Respiratory viral infections (RVIs) were the most common late infections (37/89 events), and the proportion of severe RVIs did not decline over time. Early infection (OR, 2.96; 95% CI, 1.32-6.87; p 0.009) was associated with infection between days 31 and 365. No predictors of infections beyond 1 year were identified. Fungal infections were uncommon (6% of cohort, 17/291) but showed a distinct risk profile. Cumulative dexamethasone exposure and antecedent bacterial infection were associated with invasive fungal disease in multivariable analysis (p <0.05). A threshold of ≥56 mg dexamethasone-equivalent within the first 28 days predicted fungal risk (95% CI, 1.6-27.1; area under the curve, 0.71; p 0.015). CONCLUSIONS: Late infections were common and clinically significant, with RVIs remaining a major source of morbidity. Fungal infection risk was associated with corticosteroid exposure extending beyond 6 months, supporting ongoing infection surveillance and prevention strategies beyond the first postinfusion year.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Reynolds GK, Dowling MR, Belbachir S, et al. Persistent and pathogen-specific infection risk during long-term survivorship after CD19 chimeric antigen receptor T-cell therapy: an Australian multicentre cohort study. Clin Microbiol Infect. 2026. PMID: 42341925. doi:10.1016/j.cmi.2026.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。